This page is under construction. Professors introduced at the December 2014 Faculty of Medicine meeting will be available in January 2015. Please check back soon.
Please click here to view event photos from previous Faculty of Medicine meetings and the most recent May 22, 2014 meeting
Dr. Armstrong is Professor of Medicine at Massachusetts General Hospital where she is Chief of the Department of Medicine. Focusing at the interface of genomics, cancer and social policy, she has translated genomics advances into improvements in cancer control and identified novel mechanisms underlying cancer disparities. Currently, her research seeks to improve outcomes of breast cancer screening through personalized approaches.
Angela M. Bader
Dr. Bader is Professor of Anaesthesia at Brigham and Women’s Hospital and is a recognized leader in the area of perioperative medicine and preoperative risk assessment. Her work includes development of a new multidisciplinary patient-centered, value-based practice model for pre-procedure evaluation. This model is now used as an international benchmark for excellence in pre-procedure evaluation.
Dr. Bernstein is Professor of Pathology at Mass General Hospital and co-Director of the Epigenomics Program at the Broad Institute. He has pioneered the study of chromatin and epigenetics at a genome-wide scale. His work is notable for the discovery of epigenetic mechanisms in pluripotent stem cells, the systematic identification of enhancer ‘switches’ in the human genome that coincide with genetic variants associated with common diseases, and the characterization of aberrant regulatory circuits in cancer.
Martha L. Bulyk
Dr. Bulyk is Professor of Medicine at Brigham and Women’s Hospital and a recognized leader in studies of transcription factors and DNA regulatory elements. She has developed high-throughput technologies to analyze transcription factors’ DNA binding specificities. Dr. Bulyk also studies the activities of transcriptional enhancers to understand how transcriptional regulatory information is encoded in the genome.
Alfred E. Buxton
Dr. Buxton is Professor of Medicine at the Beth Israel Deaconess Medical Center where he directs the Clinical Cardiac Electrophysiology Laboratory and the Fellowship Program. He is a recognized leader for developing methods on utilizing implantable cardiac defibrillators to reduce the risk for sudden cardiac death along with developing methods that identify individuals at risk for sudden cardiac death. He is also studying the mechanisms underlying the emergence of spontaneous ventricular arrhythmias after myocardial infarction and non-ischemic cardiomyopathy.
Lee S. Cohen
Dr. Cohen is Professor of Psychiatry at Mass General Hospital where he is the Founder and Director of the Center for Women’s Mental Health. He is a pioneer in the field with subspecialty research and clinical interest in psychiatric disorders during pregnancy, the post-partum period, depression in midlife women and issues related to infertility. His research aims to inform the care of patients who suffer from psychiatric illness during these critical times.
Donald E. Cutlip
Dr. Cutlip is Professor of Medicine at the Beth Israel Deaconess Medical Center. He is Section Chief of Interventional Cardiology at BIDMC and Executive Director of Clinical Investigation at the Harvard Clinical Research Institute. His work on improving and standardizing the methods for the assessment of clinical outcomes of coronary artery disease treatment has had a substantial impact on clinical practice and the design of future research.
Laurence M. Epstein
Dr. Epstein is Professor of Medicine at Brigham and Women’s Hospital where he is the Chief of the Cardiac Arrhythmia Service and Director of the Electrophysiology Laboratory in the BWH Heart and Vascular Center. He is a pioneer in developing novel treatment options for cardiac arrhythmias. His clinical and research interest is currently focused on safe and effective pacemaker and ICD lead management, medical simulation and healthcare economics.
James A. Gordon
Dr. Gordon is Professor of Medicine at Mass General Hospital, where he serves as Director of the MGH Learning Laboratory and Chief of the Division of Medical Simulation in the hospital’s Department of Emergency Medicine. He also directs the Gilbert Program in Medical Simulation at Harvard Medical School and co-founded the Institute for Medical Simulation at the Center for Medical Simulation in Boston. Dr. Gordon’s work focuses on the use of immersive clinical training environments to enhance quality and safety in health care.
Timothy A. Graubert
Dr. Graubert is Professor of Medicine at Mass General Hospital where he is the Director of the MGH Hematologic Malignancies Program. His work has helped to define the genetic basis of human myeloid leukemias. His current research is focused on families with an inherited predisposition to myeloid leukemia with an aim to identify new genes that confer increased susceptibility and genes that, when mutated, somatically cooperate with inherited variants that result in leukemia.
Dr. Grodstein is Professor of Medicine at Brigham and Women’s Hospital where she is the Director of the Nurses’ Health Study, one of the premier research studies of women’s health and chronic disease prevention. She has pioneered large-scale studies of cognitive decline in older women as part of her research focus on aging. She has recently focused on applying novel computerized techniques for measuring cognitive function in younger persons and identifying health and lifestyle factors which determine the earliest stages of cognitive decline.
Eva C. Guinan
Dr. Guinan is Professor of Radiation Oncology at the Dana-Farber Cancer Institute where she serves as the Department’s Director of Translation Research. She is a noted clinical and translational innovator in the field of stem cell transplantation. Her laboratory is currently focused on developing a novel and promising approach to human radiation mitigation and protection by modulating endotoxin-related innate immunity.
Mukesh G. Harisinghani
Dr. Harisinghani is Professor of Radiology at Mass General Hospital where he serves as the Director of Abdominal MRI and Director of the Clinical Discovery Program. He is a pioneer in translating novel techniques for clinical imaging and bringing these from the bench to the bed side. He was one of the first to apply lymphotrophic nanoparticle enhanced MRI to enhance the accuracy of nodal staging in patients with primary GU cancers, and he continues to study this technique in the setting of cancer and autoimmune diseases.
Dr. Hoffmann is Professor of Radiology at Mass General Hospital where he is the Chief of the Division of Cardiac Imaging in the Department of Radiology and the Director of the Cardiac MR PET CT Program. He is a pioneer in noninvasive cardiovascular imaging. His main interest is to translate advanced coronary atherosclerosis imaging to improved cardiovascular risk assessment, patient management, and outcomes in both asymptomatic and symptomatic individuals in a safe and cost effective manner.
Victor W. Hsu
Dr. Hsu is Professor of Medicine at Brigham and Women’s Hospital. His research has advanced our understanding of intracellular transport, a critical process for the proper localization of proteins and membranes. He has applied insights gained from these studies to better understand diseases such as cancer, diabetes and viral pathogenesis.
Dr. Ichinose is Professor of Anaesthesia at Mass General Hospital where he is the Director of the Resuscitation Science Laboratory of the Anesthesia Center for Critical Care Research. Work in his laboratory has revealed the unique cytoprotective effects of nitric oxide and hydrogen sulfide. Ongoing studies are directed towards understanding how nitric oxide and hydrogen sulfide protect cells and will translate into benefiting patients who are suffering from critical illness.
Terrie E. Inder
Dr. Inder is chair of Pediatric Newborn Medicine at the Brigham and Women’s Hospital and a Professor of Pediatrics at HMS. As a dual boarded child neurologist and neonatologist, Dr. Inder’s major discoveries have been in clinical and translational research into the nature and timing of brain injury in preterm and high-risk term born infants. Moreover, she is poised to identify early interventions that will reduce the severity of neurologic injury and developmental disabilities in newborns with encephalopathy.
Pasi A. Jӓnne
Dr. Jänne is a Professor of Medicine at the Dana Farber Cancer Institute where he is the Director of the Lowe Center for Thoracic Oncology. His translational and clinical research focuses on the therapeutic implications of oncogenic alterations in lung cancer. Work from his laboratory has led to numerous clinical trials and novel treatment approaches for patients with lung cancer.
Keith A. Johnson
Dr. Johnson is Professor of Radiology at Massachusetts General Hospital where he is the Director of Molecular Neuroimaging. Dr. Johnson specializes in dementing disorders and uses a novel in vivo PET technique to detect protein deposits. He has also made substantial contributions in the area of nuclear medicine and molecular imaging, particularly in the case of degenerative disorders of the central nervous system.
Paula A. Johnson
Dr. Johnson is Professor of Medicine at Brigham and Women’s Hospital, the Executive Director of the Connors Center for Women’s Health and Gender Biology and Chief of the Division of Women’s Health. She has served as a member of the NIH Advisory Committee on Research on Women’s Health and the Institute of Medicine Committee on Preventive Services for Women, which led to the coverage of preventive services for women under the Affordable Care Act. Her most recent work focuses on the impact of U.S. health care reform on women, advancing sex-specific research, and defining leadership and developing training to advance the health of women globally.
Andrzej S. Krolewski
Dr. Krolewski is Professor of Medicine at the Joslin Diabetes Center where he is the Head of the Section of Genetics and Epidemiology. He conducts multidisciplinary research on the etiology of kidney complications of diabetes in humans, which has resulted in identifying early progressive renal decline, the initial disease process leading to impaired renal function and renal failure. He has used technology to identify biomarkers of renal decline and to identify potential therapeutic targets to delay the onset of renal failure.
James B. Meigs
Dr. Meigs is Professor of Medicine at Mass General Hospital where he is the Co-Director of the MGH Clinical Research Program Clinical Effectiveness Research Group. His research has advanced knowledge of the epidemiology, prevention and care of metabolic syndrome and cardiovascular disease in type 2 diabetes. More recently, he has studied the genetic basis of glucose and insulin regulation and risk of type 2 diabetes.
Joshua P. Metlay
Dr. Metlay is Professor of Medicine at Mass General Hospital where he is Chief of the Division of General Internal Medicine, which includes programs in primary care and hospital medicine. His research focuses on the development and evaluation of diagnostic and therapeutic strategies for the management of patients with acute respiratory infections. In addition, he has investigated the mechanisms by which antimicrobial drug resistance emerges and spreads among clinical isolates of Streptococcus pneumoniae.
Nikhil C. Munshi
Dr. Munshi is Professor of Medicine at the Veterans Affairs Boston Healthcare system. He is also the Director of Basic and Correlative Sciences at the Jerome Lipper Myeloma Center at the Dana-Farber Cancer Institute. Work in his lab has described the mutational landscape in myeloma, defined genomic heterogeneity and its evolution, validated a number of targeted agents, and characterized immune status which has led to developing vaccination approaches for myeloma.
Dr. Nosé is Professor of Pathology at Mass General Hospital where she is the Associate Chief of Pathology and the Director of Anatomic and Molecular Pathology. Her major research interest is endocrine pathology, particularly thyroid pathology, familial tumor syndromes, and the genetic predispositions that underlie neoplasms. These include multiple endocrine neoplasia syndromes type 1 and 2, as well as other familial syndromes.
Dr. Paulsson is Professor of Systems Biology at Harvard Medical School. He is a pioneer in the field of biological stochasticity and has contributed to how molecular stochasticity influences biological control mechanisms. He has also made important methodological advances in overcoming limitations arising from artifactual multimerization of proteins due to fluorescent tags.
Phillip L. Pearl
Dr. Pearl is Professor of Neurology at Boston Children’s Hospital. He is a recognized leader in inherited metabolic epilepsies as well as education in neurology. His research has focused on pediatric neurotransmitter disorders, with particular emphasis in disorders of GABA metabolism, including the characterization and first clinical trials of succinic semialdehyde dehydrogenase deficiency.
Diego A. Pizzagalli
Dr. Pizzagalli is Professor of Psychiatry at McLean Hospital where he is the Director of the Center for Depression, Anxiety and Stress Research and the Director of the McLean Imaging Center. His work combines multiple neuroimaging methods and has contributed to a better understanding of key psychological, environmental, and neurobiological factors implicated in depression. He has also identified biomarkers associated with clinically important aspects of depression, including individual differences, stress sensitivity, and response to antidepressant treatment.
Dr. Puder is Professor of Surgery at Boston Children’s Hospital. He is a leader in the field of fatty acid biology and intestinal failure and has developed several novel therapies to treat parenteral nutrition associated liver disease by using intravenous lipid emulsions. His current work focuses on developing more advanced lipid emulsions and investigating how essential fatty acids can be used as pharmacologic modalities for a variety of diseases.
Douglas E. Raines
Dr. Raines is Professor of Anaesthesia at Mass General Hospital. He is a recognized leader in the study of general anesthetic mechanisms of action. He is also a pioneer in developing new intravenous general anesthetics, some of which possess very brief and predictable durations of action and have reduced side effects.
Dr. Rudolph is Professor of Psychiatry at McLean Hospital where he directs the Laboratory of Genetic Neuropharmacology. He has made major contributions to our understanding of the physiological and pharmacological functions of inhibitory neurotransmitter receptor subtypes in the brain. These advances have led to designing novel therapeutic approaches to treating disorders such as anxiety, spasticity and chronic pain.
Marc S. Sabatine
Dr. Sabatine is Professor of Medicine at Brigham and Women’s Hospital. He is the Chairman of the Thrombolysis in Myocardial Infarction Study Group, which conducts large-scale international clinical trials that have shaped the practice of cardiovascular medicine. Additional research focuses on the use of proteomics and genomics to refine patient prognosis and tailor interventions in order to help realize the goal of personalized medicine.
Dr. Salim is Professor of Surgery at Brigham and Women’s Hospital where he is Chief of the Division of Trauma, Burn and Surgical Critical Care. He is a recognized leader in Trauma Surgery and has focused his research on the care and outcomes of trauma patients. His most recent research has focused on disparities in organ donation and improving overall donation rates, in particular among Hispanic Americans.
Michael A. Schwarzschild
Dr. Schwarzschild is Professor of Neurology at Massachusetts General Hospital and leads the North American Parkinson Study Group, conducting clinical trials to improve therapies for Parkinson’s disease. His research has identified the neuroprotective potential and mechanisms of purines such as caffeine and urate. His group’s findings have provided a biological basis for established epidemiology of Parkinson’s, and have accelerated clinical development of adenosine receptor antagonists and the urate precursor inosine for treating the disease.
Ramesh A. Shivdasani
Dr. Shivdasani is Professor of Medicine at the Dana-Farber Cancer Institute and is Co-Director of the Cancer Program in the Harvard Stem Cell Institute. His work has made valuable contributions toward understanding the transcriptional basis for cell differentiation in two self-renewing tissues, namely blood and intestine. His lab investigates how transcription factors and chromatin interpret local signals to express tissue-specific genes in normal and cancer cells within the digestive tract.
Dr. Tsao is Professor of Dermatology at Mass General Hospital where he is the Director of both the MGH Melanoma and Pigmented Lesion Center and the MGH Melanoma Genetics Program. He is a recognized leader in melanoma genetics and has pioneered several molecular tools for melanoma risk prediction. Dr. Tsao has also introduced novel strategies in molecular therapeutics for advanced melanoma.
Helen H. Wang
Dr. Wang is Professor of Pathology at the Beth Israel Deaconess Medical Center where she is the Medical Director of Cytopathology. She is a recognized expert in breast, thyroid, and GI cytopathology. Combining her expertise in biostatistics, epidemiology, and pathology, she has been instrumental in incorporating statistical methods and has pioneered evidence-based practice in cytopathology by proposing a probabilistic approach in reporting cytopathology results.
D. Bradley Welling
Dr. Welling is Professor and Chair of the Department of Otology and Laryngology at Harvard Medical School and chief of otolaryngology at the Mass Eye and Ear Infirmary and Mass General Hospital. He has made major contributions to understanding the molecular mechanisms of vestibular schwannomas and meningiomas in patients with neurofibromatosis type 2. His current clinical and research focus is on targeted therapy for NF2 patients.
William M. Wells III
Dr. Wells is Professor of Radiology at Brigham and Women’s Hospital where he is the Chief Scientist in the BWH Surgical Planning Laboratory. He is widely known for his pioneering work in medical image segmentation and registration. He is currently investigating research in algorithms for image-guided therapy and general medical image analysis.
Dr. Wong is Professor of Medicine at the Dana-Farber Cancer Institute where he is the scientific co-director of the Belfer Institute for Applied Cancer Science. He has developed novel genetically engineered mouse models of lung cancer based on specific genetic alterations. These models have proved invaluable for understanding the molecular mechanisms of lung cancer initiation and progression and for novel targeted therapeutic testing.